Fatih Ayoglu Appointed Business Development Manager—EMEA at Catheter Precision

Catheter Precision Inc. has appointed Fatih Ayoglu to the newly created position of Business Development Manager—EMEA. Ayoglu will oversee clinical and sales development of Catheter Precision products in Europe, the Middle East and Africa and will report to Chief Commercial Officer Patricia Kennedy. 
 
“Fatih’s success in sales and clinical development at major medical device companies with a specific focus on cardiac electrophysiology makes him ideal for this position,” Catheter Precision CEO David Jenkins said. “We look forward to drawing on his expertise to support our overall business and product development goals, as well as his extensive industry knowledge and contacts to broaden our global footprint, including a planned expansion into the Middle East in the first half of 2023.”
 
Ayoglu brings to Catheter Precision more than a decade of medical device industry experience. Most recently, he was sales manager for Circle Cardiovascular Imaging Inc., the global leader in cardiovascular imaging solutions. Prior to that, he served as technical sales specialist at Biosense Webster Inc., the cardiac electrophysiology unit of Johnson & Johnson, and as territory management for Abbott Laboratories. He earned an MSc degree in engineering business management from the University of Warwick in the United Kingdom and a master of science degree in electrical and electronics engineering from Koç University in Istanbul.
 
Catheter Precision’s lead product, VIVO (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. Food and Drug Administration (FDA) and has been awarded the CE mark. The company also intends to pursue a second generation of Amigo, a previously FDA-cleared and CE mark robotic arm that can be used to remotely control catheters outside of the procedure room. Additionally, Catheter Precision is working toward a commercial launch of a vessel closure device, currently planned for the first half of 2023.
 
“I am proud to join Catheter Precision at this important juncture in the company’s development and look forward to leveraging my extensive network of cardiology and industry contacts to drive awareness and reach of our growing product portfolio,” Ayoglu said. “From my base in Birmingham, England, I look forward to developing new relationships for Catheter Precision within the United Kingdom and across Europe.”
 
On Sept. 12, Catheter Precision announced a merger agreement with Ra Medical Systems, which, if completed, will result in a combined publicly traded company focusing on the cardiac electrophysiology market. Under terms of the agreement, Catheter Precision will become a wholly owned subsidiary of Ra Medical Systems in a stock-for-stock reverse merger transaction. The merger is expected to close before the end of 2022, subject to satisfying certain closing conditions, including the receipt of shareholder approval by both companies.
 
Catheter Precision is a medical device company bringing new solutions to market to improve cardiac arrhythmia treatment. It is focused on developing technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
 
Ra Medical Systems Inc. is a medical device company that owns intellectual property related to an advanced excimer laser-based platform for use in the treatment of vascular immune-mediated inflammatory diseases. Its excimer laser and single-use catheter system, together referred to as the DABRA Excimer Laser System, is used as a tool in the treatment of peripheral artery disease.